Pertussis: History of the Disease and Current Prevention Failure
Pertussis or whooping cough has been given many names over the centuries. It was first recognized in the Middle Ages and since then various epidemics have been described. Jules Bordet and Octave Gengou isolated Bordetella pertussis, a causative agent for whooping cough, in Paris more than 100 years ago, which created an excellent opportunity to invent a vaccine. In 1914 the whole-cell pertussis vaccine was invented, then in the 1940s it was combined with tetanus and diphtheria toxoids to become DTP and it became widely available. A successive decrease in the incidence of the disease has since been observed. The vaccine has been about 80 % effective in preventing serious disease and death from pertussis. The disadvantage is that the vaccine offers protection for 5–10 years after the last dose of the full vaccination course. The second issue is the question of how to prevent side effects of the whole-cell vaccine. In the 1990s, the acellular vaccine was introduced in the US and gradually replaced the whole-cell vaccine. About 10 years later, a possible failure with the new vaccine has been observed, that is a lack of long-term protection. Nowadays, both vaccines are used, with the acellular vaccine being vastly predominant in most developed countries. Pertussis incidence has increased since the 1980s, but new prevention strategies include booster doses for specific age groups.
KeywordsInfection Immunization Pertussis vaccine Prevention Prophylaxis Whooping cough
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- ACIP (1992) Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use – Supplementary ACIP statement recommendations of the immunization practices advisory committee. MMRW Rec Rep Feb. 07, 1992/41 (RR-1); 1–10. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00041801.htm. Accessed on 5 Feb 2016
- ACIP (1997) Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP) MMRW Rec and Rep March 28, 1997/46 (RR-7); 1–25. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00048610.htm. Accessed on 5 Feb 2016
- Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV, Advisory Committee on Immunization Practices (ACIP) (2006) Advisory Committee on Immunization Practices (ACIP) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-3):1–34Google Scholar
- Cherry JD, Brunnel PA, Golden GS, Karzon DT (1988) Report of the task force on pertussis and pertussis immunization – 1988. Pediatrics 81:933–984Google Scholar
- ECDC (2014) European Center for Disease Prevention and Control. Annual epidemiological report 2014 – vaccine-preventable diseases. Available from: http://ecdc.europa.eu/en/publications/Publications/AER-2014-VPD-FINAL.pdf. Accessed on 5 Feb 2016
- Morgan LG (1997) Pertussis immunization: an update. J Can Chiropr Assoc 41(2):86–90Google Scholar
- Weston R (2012) Whooping cough: a brief history to the 19th century. Can Bull Med Hist/Bulletin canadien d’histoire de la médecine 29:329–349Google Scholar
- WHO/UNICEF (2015) Global immunization data. Available from: http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf?ua=. Accessed on 5 Feb 2016